期刊文献+

Hepatitis C virus: Promising discoveries and new treatments 被引量:2

Hepatitis C virus: Promising discoveries and new treatments
下载PDF
导出
摘要 Despite advances in therapy, hepatitis C virus(HCV) infection remains an important global health issue. It is estimated that a significant part of the world population is chronically infected with the virus, and many of those affected may develop cirrhosis or liver cancer. The virus shows considerable variability, a characteristic that directly interferes with disease treatment. The response to treatment varies according to HCV genotype and subtype. The continuous generation of variants(quasispecies) allows the virus to escape control by antivirals. Historically, the combination of ribavirin and interferon therapy has represented the only treatment option for the disease. Currently, several new treatment options are emerging and are available to a large part of the affected population. In addition, the search for new substances with antiviral activity against HCV continues, promising future improvements in treatment. Researchers should consider the mutation capacity of the virus and the other variables that affect treatment success. Despite advances in therapy, hepatitis C virus (HCV) infection remains an important global health issue. It is estimated that a significant part of the world population is chronically infected with the virus, and many of those affected may develop cirrhosis or liver cancer. The virus shows considerable variability, a characteristic that directly interferes with disease treatment. The response to treatment varies according to HCV genotype and subtype. The continuous generation of variants (quasispecies) allows the virus to escape control by antivirals. Historically, the combination of ribavirin and interferon therapy has represented the only treatment option for the disease. Currently, several new treatment options are emerging and are available to a large part of the affected population. In addition, the search for new substances with antiviral activity against HCV continues, promising future improvements in treatment. Researchers should consider the mutation capacity of the virus and the other variables that affect treatment success.
出处 《World Journal of Gastroenterology》 SCIE CAS 2016年第28期6393-6401,共9页 世界胃肠病学杂志(英文版)
关键词 HEPATITIS C INFECTION HEPATITIS C VIRUS TREATMENTS ANTIVIRAL research Hepatitis C infection Hepatitis C virus Treatments Antiviral research
  • 相关文献

参考文献85

  • 1Simmonds P.Genetic diversity and evolution of hepatitis C virus--15 years on. Journal of General Virology . 2004
  • 2WHO.Hepatitis C Fact sheet N°164. http://www.who.int/mediacentre/factsheets/fs164/en/ . 2015
  • 3Usman Ashfaq,Tariq Javed,Sidra Rehman,Zafar Nawaz,Sheikh Riazuddin.Inhibition of HCV 3a core gene through Silymarin and its fractions. Virology Journal . 2011
  • 4Wagoner Jessica,Morishima Chihiro,Graf Tyler N,Oberlies Nicholas H,Teissier Elodie,Pécheur Eve-Isabelle,Tavis John E,Polyak Stephen J.Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PloS one . 2011
  • 5Finkielsztein L M,Moltrasio G Y,Caputto M E,Castro E F,Cavallaro L V,Moglioni A G.What is known about the antiviral agents active against bovine viral diarrhea virus (BVDV)?. Current Medicinal Chemistry . 2010
  • 6Calland Noémie,Dubuisson Jean,Rouillé Yves,Séron Karin.Hepatitis C virus and natural compounds: a new antiviral approach?. Viruses . 2012
  • 7McHutchison John G,Lawitz Eric J,Shiffman Mitchell L,Muir Andrew J,Galler Greg W,McCone Jonathan,Nyberg Lisa M,Lee William M,Ghalib Reem H,Schiff Eugene R,Galati Joseph S,Bacon Bruce R,Davis Mitchell N,Mukhopadhyay Pabak,Koury Kenneth,Novie.Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. The New England Quarterly . 2009
  • 8Davis G L,Esteban-Mur R,Rustgi V,Hoefs J,Gordon S C,Trepo C,Shiffman M L,Zeuzem S,Craxi A,Ling M H,Albrecht J.Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. The New England Quarterly . 1998
  • 9Zeuzem Stefan,Andreone Pietro,Pol Stanislas,Lawitz Eric,Diago Moises,Roberts Stuart,Focaccia Roberto,Younossi Zobair,Foster Graham R,Horban Andrzej,Ferenci Peter,Nevens Frederik,Müllhaupt Beat,Pockros Paul,Terg Ruben,Shouval Daniel,van Ho.Telaprevir for retreatment of HCV infection. The New England Quarterly . 2011
  • 10Jacobson Ira M,McHutchison John G,Dusheiko Geoffrey,Di Bisceglie Adrian M,Reddy K Rajender,Bzowej Natalie H,Marcellin Patrick,Muir Andrew J,Ferenci Peter,Flisiak Robert,George Jacob,Rizzetto Mario,Shouval Daniel,Sola Ricard,Terg Ruben A,Yos.Telaprevir for previously untreated chronic hepatitis C virus infection. The New England Quarterly . 2011

二级参考文献349

  • 1Rafiei A,Darzyani Azizi M,Taheri S,Haghshenas MR,Hosseinian A,Makhlough A.Genetic diversity of HCV among various high risk populations(IDAs,thalassemia,hemophilia,HD patients) in Iran[J].Asian Pacific Journal of Tropical Medicine,2013,6(7):556-560. 被引量:2
  • 2[57]Puig-Basagoiti F,Forns X,Furcic I,Ampurdanes S,Gimenez-Barcons M,Franco S,Sanchez-Tapias JM,Saiz JC.Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C.J Gen Virol 2005; 86:1067-1075
  • 3[58]Houghton M.Hepatitis C virus.In:Howley DMKPM.Fields Virology.Philadelphia:Lippincott-Raven,1996:1035-1058
  • 4[59]Farci P,Purcell RH.Clinical significance of hepatitis C virus genotypes and quasispecies.Semin Liver Dis 2000; 20:103-126
  • 5[60]Bartenschlager R.The NS3/4A proteinase of the hepatitis C virus:unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy.J Viral Hepat 1999; 6:165-181
  • 6[61]Vallet S,Gouriou S,Nousbaum JB,Legrand-Quillien MC,Goudeau A,Picard B.Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients.J Med Virol 2005; 75:528-537
  • 7[62]Vallet S,Gouriou S,Nkontchou G,Hotta H,Vilerio M,Legrand-Quillien MC,Beaugrand M,Trinchet JC,Nousbaum JB,Deny P,Gaudy C,Goudeau A,Picard B,Payan C.Is hepatitis C virus NS3 protease quasispecies heterogeneity predictive of progression from cirrhosis to hepatocellular carcinoma?J Viral Hepat 2007; 14:96-106
  • 8[63]Soderholm J,Ahlen G,Kaul A,Frelin L,Alheim M,Barnfield C,Liljestrom P,Weiland O,Milich DR,Bartenschlager R,Sallberg M.Relation between viral fitness and immune escape within the hepatitis C virus protease.Gut 2006; 55:266-274
  • 9[64]Gale M,Jr.Effector genes of interferon action against hepatitis C virus.Hepatology 2003; 37:975-978
  • 10[65]Meylan E,Curran J,Hofmann K,Moradpour D,Binder M,Bartenschlager R,Tschopp J.Cardif is an adaptor protein in the RIG-Ⅰ antiviral pathway and is targeted by hepatitis C virus.Nature 2005; 437:1167-1172

共引文献57

同被引文献3

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部